Form 10-Q Checkpoint Therapeutics, For: Jun 30
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/11/2026
- Wall Street ends down as US-Iran peace optimism fades
- S&P 500 EPS growth above 20% is rare. Why 2027 may be at risk
- Goldman Sachs warns AI investment may be crowding out other business spending
- Why Wednesday's inflation print could provide the next dovish catalyst
- Tesla needs Robotaxi flywheel proof to boost investor conviction: Morgan Stanley
- After-Hours Movers: CRWV, NBIS, SMCI, LITE, CAVA, HRB
- After-Hours Movers: P, RIOT, BW, RKLB, HIMS, UPWK
- After-Hours Movers: TEAM, NET, TWLO, DOCS, FROG, DV, TTD, ABNB, DKNG, SG, RKT
- After-Hours Stock Movers: WDC, SNDK, FIG, APP, HUBS, SOUN, DASH, XYZ, Z, FLNC
- After-Hours Movers: SPCX, AMD, ANET, PINS, APPS, UPST, ZETA, BKNG, LCID, CPNG, MTCH
Fortress Biotech (FBIO) PT Raised to $13 at Roth/MKM
August 14, 2024 5:06 AM EDTRoth/MKM analyst Jason Whittes raised the price target on Fortress Biotech (NASDAQ: FBIO) to $13.00 (from $10.00) while maintaining a Buy rating.
The analyst comments "FBIO reported 2Q24 revenues down 14.4% to $14.9 million vs. consensus of $14.8 million and our estimate of $14.0 million. EPS was ($0.73) vs.... More
